Rapid and quantitative automated measurement of bacteriophage activity against cystic fibrosis isolates of Pseudomonas aeruginosa

被引:22
作者
Cooper, C. J. [1 ]
Denyer, S. P. [1 ]
Maillard, J. -Y. [1 ]
机构
[1] Cardiff Univ, Welsh Sch Pharm, Cardiff CF10 3NB, S Glam, Wales
关键词
bacteriophage; lytic activity; Pseudomonas aeruginosa; STRAIN; ASSAY; SUSCEPTIBILITY; AMPLIFICATION; INFECTIONS; BIOFILMS; EFFICACY; SPREAD;
D O I
10.1111/j.1365-2672.2010.04928.x
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Pseudomonas aeruginosa is an opportunistic pathogen and is the main cause of respiratory infection in cystic fibrosis patients. Most strains prevalent within the UK are resistant to two or more antibiotics leading to the search for new therapeutic strategies including the use of bacteriophages. Methods and Results: The infectivity of four bacteriophages was increased using an enhancement protocol based on the use of pomegranate rind extract. Their efficacy against 14 Ps. aeruginosa strains was measured using a qualitative streak test and a novel quantitative assay based on the Bioscreen C microbial growth analyzer. Streak test analysis illustrated an increase in the lytic activity of enhanced bacteriophages, whereas Bioscreen analysis showed that both enhanced and unenhanced bacteriophages failed to meet acceptable levels of activity in c. 50% of strains tested. Conclusions: The quantitative Bioscreen C analyzer showed comparable but not identical results in phage activity and identified significant bacterial re-growth by 20 h postinfection. Significance and Impact of the Study: With the resurgence of interest in bacteriophage therapy against infectious bacterial diseases, a rapid high throughput quantitative method for screening phage activity and bacterial resistance is required. The use of the Bioscreen C analyzer meets these criteria and was shown to be more stringent than the traditional streak test.
引用
收藏
页码:631 / 640
页数:10
相关论文
共 50 条
  • [21] COMPARISON OF INHIBITORY AND BACTERICIDAL ACTIVITY OF ANTIPSEUDOMONAL ANTIBIOTICS AGAINST PSEUDOMONAS-AERUGINOSA ISOLATES FROM CYSTIC-FIBROSIS PATIENTS
    ANSORG, R
    MULLER, KD
    WIORA, J
    CHEMOTHERAPY, 1990, 36 (03) : 222 - 229
  • [22] PREVALENCE OF VIRULENCE GENES AMONG BULGARIAN NOSOCOMIAL AND CYSTIC FIBROSIS ISOLATES OF PSEUDOMONAS AERUGINOSA
    Mitov, Ivan
    Strateva, Tanya
    Markova, Boyka
    BRAZILIAN JOURNAL OF MICROBIOLOGY, 2010, 41 (03) : 588 - 595
  • [23] In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients
    Monogue, Marguerite L.
    Desai, Dhara
    Pybus, Christine A.
    Sanders, James M.
    Clark, Andrew E.
    Greenberg, David E.
    MICROBIOLOGY SPECTRUM, 2023, 11 (06):
  • [24] COMPARISON OF THE WORLDWIDE TRANSMISSIBLE PSEUDOMONAS AERUGINOSA WITH ISOLATES FROM BRAZILIAN CYSTIC FIBROSIS PATIENTS
    Leao, Robson Souza
    Carvalho-Assef, Ana Paula D.
    Ferreira, Alex Guerra
    Folescu, Tania Wrobel
    Barth, Afonso Luis
    Pitt, Tyrone Leslie
    Marques, Elizabeth Andrade
    BRAZILIAN JOURNAL OF MICROBIOLOGY, 2010, 41 (04) : 1079 - 1081
  • [25] Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
    Olivares, Elodie
    Badel-Berchoux, Stephanie
    Provot, Christian
    Jaulhac, Benoit
    Prevost, Gilles
    Bernardi, Thierry
    Jehl, Francois
    FRONTIERS IN MICROBIOLOGY, 2017, 8
  • [26] Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients
    Islam, S.
    Oh, H.
    Jalal, S.
    Karpati, F.
    Ciofu, O.
    Hoiby, N.
    Wretlind, B.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (01) : 60 - 66
  • [27] Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis
    Waters, V.
    Zlosnik, J. E. A.
    Yau, Y. C. W.
    Speert, D. P.
    Aaron, S. D.
    Guttman, D. S.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (12) : 3341 - 3350
  • [28] Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review
    Rossitto, Martina
    Fiscarelli, Ersilia V.
    Rosati, Paola
    FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [29] Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: A review
    Ratjen, Felix
    Brockhaus, Florian
    Angyalosi, Gerhild
    JOURNAL OF CYSTIC FIBROSIS, 2009, 8 (06) : 361 - 369
  • [30] Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres
    Smith, Daniel J.
    Ramsay, Kay A.
    Yerkovich, Stephanie T.
    Reid, David W.
    Wainwright, Claire E.
    Grimwood, Keith
    Bell, Scott C.
    Kidd, Timothy J.
    RESPIROLOGY, 2016, 21 (02) : 329 - 337